

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

**EuroEyes International Eye Clinic Limited**

德視佳國際眼科有限公司

(Stock Code: 1846.HK)

## **EuroEyes Group Acquires FYEO Europe B.V. at an Enterprise Value of EUR 135 million**

*Strengthening EuroEyes' Position in the European Refractive Surgery Market*

(Hong Kong, 27 February 2026) – [EuroEyes International Eye Clinic Limited](#) (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1846), a leading global refractive surgery group, today announced that EuroEyes Netherlands (the “Purchaser”), a wholly-owned subsidiary of the Group, has conditionally agreed to purchase, and the five shareholders of [FYEO Europe B.V.](#) (“FYEO”) have conditionally agreed to sell and transfer the entire issued share capital of FYEO, strategically expanding EuroEyes’ Footprint into Netherlands.

Under the terms of the agreement, FYEO will be acquired at an enterprise value of **EUR135 million** on a cash-free and debt-free basis. This valuation corresponds to an EV/EBITDA multiple of approximately 10.2 times based on FYEO’s unaudited reported EBITDA of approximately EUR13.17 million for FY2025 and approximately 9.8 times based on unaudited normalized EBITDA of approximately EUR13.72 million, which is within the range of recent European private healthcare transactions. On a debt-free and cash-free basis, the equity consideration amounts to approximately EUR131.8 million. The transaction is structured on a locked box basis and remains subject to shareholder approval and customary closing conditions. Completion is expected in mid-2026.

The acquisition will be financed through a combination of the Group's internal resources, a fully underwritten EUR75 million syndicated euro term loan facility provided by UniCredit, and a reinvestment by FYEO’s management team into EuroEyes Netherlands.

The Netherlands represents an attractive refractive surgery market, supported by favourable demographics and high levels of disposable income. FYEO is focused exclusively on refractive surgery, treating patients with presbyopia and myopia through a network of 3 clinics and 10 consultation centres across the Netherlands.

For the year ended 31 December 2025, FYEO recorded unaudited reported EBITDA of approximately EUR13.17 million and unaudited normalized EBITDA of approximately EUR13.72 million.

EuroEyes and FYEO share a pure-play refractive surgery focus and a strong emphasis on clinical excellence and patient experience. Following completion, FYEO will operate as a sub-brand under EuroEyes Netherlands, with its existing leadership team remaining in place. FYEO’s management

will reinvest into EuroEyes Netherlands, aligning long-term interests and supporting continued growth.

The acquisition is expected to broaden the Group's European footprint, enhance operational scale and strengthen its competitive positioning in the refractive surgery segment. EuroEyes and FYEO are both focused exclusively on refractive surgery.

**Dr. Jørn Slot Jørgensen, Founder, Chairman and CEO of EuroEyes**, said, "We are pleased to welcome FYEO to the EuroEyes Group. FYEO has built a strong name in the Netherlands, with the same values that are essential to us: quality, expertise and personal attention for every patient. Together, we see significant opportunities to further develop refractive surgery services across Europe."

**Mr. Rens Schoenmakers, CEO of FYEO**, said, "This step marks an important moment in FYEO's development. We will remain an organisation focused on the highest quality and personalised care. At the same time, the collaboration with EuroEyes offers the opportunity to continue to grow, learn and innovate within an international network of specialists. It is a wonderful recognition of what our team has built together."

An EGM will be convened to consider and, if thought fit, approve, among others, the Sale and Purchase Agreement and the transactions contemplated thereunder and the Subscription Agreement and the transactions contemplated thereunder. Upon completion, FYEO will become an indirect wholly owned subsidiary of the Company and its financial results will be consolidated into the financial statements of the Group.

-End-

#### **About EuroEyes International Eye Clinic Limited (1846.HK)**

EuroEyes was established in 1993 by Dr Jørn Jørgensen, an internationally recognized refractive surgeon and entrepreneur and today is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 30 years of experience with individualised patient care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Switzerland, Denmark, the PRC and the United Kingdom. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK and Presbyond®); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation). For more information, please visit [ir.euroeyes.hk](http://ir.euroeyes.hk).

#### **About FYEO Europe B.V.**

FYEO is the largest clinic group for private pay refractive surgery in the Netherlands. FYEO offers consultations and examinations for laser and lens implantation treatments at 15 locations across the Netherlands. Since its founding in 2002, a driven and enthusiastic team of approximately 350 employees and 22 specialists has treated more than 80,000 satisfied patients. For more information, visit: <https://fyeo.nl/>